EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study

Niels A D Guchelaar iD, Stefan A J Buck, Leni van Doorn, Koen G A M Hussaarts, Yorick Sandberg, Annemieke van der Padt-Pruijsten, Robbert J van Alphen, Laura Poppe-Manenschijn, Isolde Vleut, Peter de Bruijn, Roelof W F van Leeuwen, Bianca Mostert und 4 weitere

Clinical Pharmacokinetics · 2024

DOI: 10.1007/s40262-024-01390-3 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Niels A D Guchelaar und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, PO Box 2040, 3000 CA, Rotterdam, The Netherlands. n.guchelaar@era…. Hauptthemen laut MEDLINE: Cimetidine, Cross-Over Studies, Drug Interactions, Metformin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Servier.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Trifluridine/tipiracil, registered for the treatment of patients with metastatic gastric and colorectal cancer, is a substrate and inhibitor for the organic cation transporter 2 (OCT2) and the multidrug and toxin extrusion protein 1 (MATE1), which raises the potential for drug-drug interactions with other OCT2/MATE1 modulators. Therefore, we prospectively examined the effect of an OCT2/MATE1 inhibitor (cimetidine) and substrate (metformin) on the pharmacokinetics of trifluridine. METHODS: In this three-phase crossover study, patients with metastatic colorectal or gastric cancer were sequentially treated with trifluridine/tipiracil alone (phase A), trifluridine/tipiracil concomitant with metformin (phase B) and trifluridine/tipiracil concomitant with cimetidine (phase C). The primary endpoint was the relative difference in exposure of trifluridine assessed by the area under the curve from timepoint zero to infinity. A > 30% change in exposure was considered clinically relevant. A p-value of < 0.025 was considered significant because of a Bonferroni correction. RESULTS: Eighteen patients were included in the analysis. Metformin did not significantly alter the exposure to trifluridine (- 12.6%; 97.5% confidence interval - 25.0, 1.8; p = 0.045). Cimetidine did alter the exposure to trifluridine significantly (+ 18.0%; 97.5% confidence interval 4.5, 33.3; p = 0.004), but this increase did not meet our threshold for clinical relevance. Metformin trough concentrations were not influenced by trifluridine/tipiracil. CONCLUSIONS: Our result suggests that the OCT2/MATE1 modulators cimetidine and metformin can be co-administered with trifluridine/tipiracil without clinically relevant effects on drug exposure. CLINICAL TRIAL REGISTRATION: NL8067 (registered 04-10-2019).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CimetidineCross-Over StudiesDrug InteractionsMetforminOrganic Cation Transport ProteinsTrifluridineAdultAgedFemaleHumansMaleMiddle AgedColorectal NeoplasmsDrug CombinationsOrganic Cation Transporter 2Prospective StudiesPyrrolidinesStomach NeoplasmsThymine

Substanzen

CimetidineDrug CombinationsMetforminOrganic Cation Transport ProteinsOrganic Cation Transporter 2PyrrolidinesSLC22A2 protein, humanSLC47A1 protein, humanThymineTrifluridine

Autor:innen und Institutionen

  • Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, PO Box 2040, 3000 CA, Rotterdam, The Netherlands. n.guchelaar@erasmusmc.nl.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands.
  • Department of Internal Medicine, Elisabeth Tweesteden Hospital, Tilburg, The Netherlands.
  • Department of Internal Medicine, IJsselland Hospital, Capelle aan den IJssel, The Netherlands.
  • Department of Pharmacy, Erasmus MC, Rotterdam, The Netherlands.

ORCID-Profile: Niels A D Guchelaar

Förderung

  • Servier

Zitieren

APA

Guchelaar, N. A. D., Buck, S. A. J., van Doorn, L., Hussaarts, K. G. A. M., Sandberg, Y., van der Padt-Pruijsten, A., van Alphen, R. J., Poppe-Manenschijn, L., Vleut, I., de Bruijn, P., van Leeuwen, R. W. F., Mostert, B., Eskens, F. A. L. M., Oomen-de Hoop, E., Koolen, S. L. W., & Mathijssen, R. H. J. (2024). The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01390-3

Vancouver

Guchelaar NAD, Buck SAJ, van Doorn L, Hussaarts KGAM, Sandberg Y, van der Padt-Pruijsten A, et al. The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01390-3

BibTeX
@article{Guchelaar2024,
  author = {Guchelaar, Niels A D and Buck, Stefan A J and van Doorn, Leni and Hussaarts, Koen G A M and Sandberg, Yorick and van der Padt-Pruijsten, Annemieke and van Alphen, Robbert J and Poppe-Manenschijn, Laura and Vleut, Isolde and de Bruijn, Peter and van Leeuwen, Roelof W F and Mostert, Bianca and Eskens, Ferry A L M and Oomen-de Hoop, Esther and Koolen, Stijn L W and Mathijssen, Ron H J},
  title = {The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study},
  journal = {Clinical Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s40262-024-01390-3}
}
Kostenlos starten →